New drug hopes to ease rare lung condition in children

NCT ID NCT07646860

Not yet recruiting Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety and tolerability of sotatercept in Japanese children aged 1 to 18 with pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs narrow, making the heart work harder. Participants receive sotatercept injections every three weeks alongside their usual PAH medications. Researchers monitor side effects, how the drug moves through the body, and whether it helps lower resistance in lung blood vessels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sotatercept
What this could lead to: If successful, this could provide a new treatment option for children with pulmonary arterial hypertension, potentially improving blood flow and easing strain on the heart.
What could go wrong: This is a small, early-phase study with only 6 participants, so results may not apply to all children. Side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.